Y-mAbs Therapeutics Q3 2024 Earnings Report $10.57 -1.22 (-10.35%) (As of 12/3/2024 ET) Y-mAbs Therapeutics EPS ResultsActual EPS-$0.16Consensus EPS -$0.14Beat/MissMissed by -$0.02One Year Ago EPS-$0.18Y-mAbs Therapeutics Revenue ResultsActual Revenue$18.46 millionExpected Revenue$23.38 millionBeat/MissMissed by -$4.92 millionYoY Revenue GrowthN/AY-mAbs Therapeutics Announcement DetailsQuarterQ3 2024Date11/8/2024TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptYMAB Earnings History I was wrong. Dead wrong. (Ad)I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. Y-mAbs Therapeutics Earnings HeadlinesY-mAbs to Participate at Citi’s 2024 Global Healthcare ConferenceNovember 27, 2024 | markets.businessinsider.comY-mAbs to Participate at Citi's 2024 Global Healthcare ConferenceNovember 27, 2024 | globenewswire.com“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.December 4, 2024 | Weiss Ratings (Ad)Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $21.38 Average PT from AnalystsNovember 24, 2024 | americanbankingnews.comY-mAbs' Omburtamab Failure: The Critical Turning Point And $19.65M Shareholder SettlementNovember 22, 2024 | benzinga.comOppenheimer Initiates Coverage of Y-mAbs Therapeutics (YMAB) with Outperform RecommendationNovember 19, 2024 | msn.comSee More Y-mAbs Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Y-mAbs Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Y-mAbs Therapeutics and other key companies, straight to your email. Email Address About Y-mAbs TherapeuticsY-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.View Y-mAbs Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report Upcoming Earnings Toronto-Dominion Bank (12/5/2024)Canadian Imperial Bank of Commerce (12/5/2024)Bank of Montreal (12/5/2024)Oracle (12/9/2024)Adobe (12/11/2024)Broadcom (12/12/2024)Costco Wholesale (12/12/2024)Accenture (12/17/2024)Micron Technology (12/18/2024)Paychex (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
